Search results for Ianalumab

Ianalumab Biosimilar – Anti-TNFRSF13C, CD268 mAb – Research Grade, ProteoGenix, PX-TA1480

Description of Ianalumab Biosimilar - Anti-TNFRSF13C, CD268 mAb - Research Grade Introduction Ianalumab Biosimilar, also known as Anti-TNFRSF13C or CD268 monoclonal antibody, is a research grade therapeutic antibody that has been developed as a biosimilar to the existing drug, Belimumab. This antibody targets the TNFRSF13C protein, also known as CD268, which plays a crucial role in the regulation of the immune system. In this article, we will discuss the structure, activity, and potential applications of Ianalumab Biosimilar. Structure of Ianalumab Biosimilar Ianalumab Biosimilar is a monoclonal antibody, which means it is produced from a single type of immune cell. It is a fully humanized antibody, meaning it is derived from human cells and therefore has a lower risk of causing an immune response in patients. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains, held together by disulfide bonds. The variable regions of the antibody, which are responsible for binding to the target protein, are highly specific for the TNFRSF13C protein. This specificity is achieved through the process of genetic engineering, where the antibody is produced by inserting the gene for the variable region into a host cell. Activity of Ianalumab Biosimilar The primary function of Ianalumab Biosimilar is to bind to the TNFRSF13C protein, which is found on the surface of immune cells called B cells. This binding prevents the TNFRSF13C protein from interacting with its natural ligands, BAFF and APRIL, which are essential for the survival and proliferation of B cells. By inhibiting the activity of TNFRSF13C, Ianalumab Biosimilar reduces the number of B cells in the body, which can be beneficial in autoimmune diseases where there is an overactive immune response. Additionally, the antibody may also modulate the production of antibodies by B cells, further regulating the immune response. Application of Ianalumab Biosimilar Ianalumab Biosimilar has the potential to be used in the treatment of various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjogren’s syndrome. These diseases are characterized by an overactive immune response, and the targeting of TNFRSF13C with Ianalumab Biosimilar can help to regulate this response and reduce the symptoms of the disease. In addition to its potential therapeutic applications, Ianalumab Biosimilar can also be used as a research tool in the study of B cell biology and the immune system. The specificity of the antibody for TNFRSF13C makes it a valuable tool for studying the role of this protein in various diseases and in normal immune function. Conclusion In summary, Ianalumab Biosimilar is a fully humanized monoclonal antibody that targets the TNFRSF13C protein. Its specific binding to this protein allows for the modulation of the immune response, making it a potential treatment option for autoimmune diseases. Additionally, the antibody can also be used as a research tool in the study of B cell biology. With its promising therapeutic and research applications, Ianalumab Biosimilar has the potential to make a significant impact in the field of immunology.

Ianalumab, Kyinno, KB-1023

Ianalumab, Abbexa, abx831439

Ianalumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFRSF13C/CD268, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ianalumab (VAY736) is a monoclonal antibody that depletes B cells and blocks B cell activating factor receptors.

Ianalumab ELISA Kit, ProteoGenix, KPTX273

Description of Ianalumab ELISA Kit The Structure of Ianalumab ELISA Kit The Ianalumab ELISA Kit is a specialized tool used for the detection and quantification of Ianalumab, a monoclonal antibody that targets the protein interleukin-6 (IL-6). This kit is designed for use in scientific research and clinical applications, and it is based on the enzyme-linked immunosorbent assay (ELISA) technique. The kit contains all the necessary components to perform the ELISA, including pre-coated microplates, standards, controls, and detection reagents. The microplates are coated with a capture antibody specific for Ianalumab, which allows for the specific binding of the antibody in the sample. The Activity of Ianalumab ELISA Kit The activity of the Ianalumab ELISA Kit is based on the principle of sandwich ELISA. In this technique, the pre-coated microplate captures the Ianalumab present in the sample. The detection reagent, which is a biotinylated detection antibody, is then added and binds to the captured Ianalumab. This forms a sandwich complex, with the Ianalumab sandwiched between the capture and detection antibodies. Next, a streptavidin-HRP conjugate is added, which binds to the biotinylated detection antibody. This complex is then visualized by adding a substrate solution, which produces a color change in the presence of the streptavidin-HRP conjugate. The intensity of the color is directly proportional to the amount of Ianalumab present in the sample. The Application of Ianalumab ELISA Kit The Ianalumab ELISA Kit has a wide range of applications in scientific research and clinical settings. One of the main applications of this kit is the quantification of Ianalumab levels in biological samples. This is particularly useful in clinical trials and studies that involve the use of Ianalumab as a therapeutic agent. In addition, the kit can also be used to measure the presence of Ianalumab in cell culture supernatants, serum, plasma, and other biological fluids. This allows for the monitoring of Ianalumab levels in different biological samples, which can provide valuable insights into the pharmacokinetics and pharmacodynamics of this therapeutic antibody. Furthermore, the Ianalumab ELISA Kit can also be used to study the expression and regulation of IL-6 in different disease states. IL-6 is a pro-inflammatory cytokine that is involved in various physiological and pathological processes. By measuring the levels of Ianalumab, which specifically targets IL-6, researchers can gain a better understanding of the role of IL-6 in different diseases and potentially develop new therapeutic strategies. Conclusion In summary, the Ianalumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Ianalumab in biological samples. Its unique design, based on the sandwich ELISA technique, allows for the accurate measurement of Ianalumab levels, making it an essential tool for research and clinical applications. By providing a detailed analysis of the structure, activity, and application of this kit, we hope to have shed light on the importance of this tool in the field of scientific research.

Ianalumab ELISA Kit, Abbexa, abx395162

Ianalumab ELISA Kit is a quantitative ELISA kit for detection of Ianalumab.Ianalumab (VAY736) is an anti-B-cell activating factor (BAFF) receptor fully human IgG1 monoclonal antibody, engineered for direct ADCC-mediated B-cell depletion, thus providing a dual mode of action and targeted approach to treat pSS. The current phase 2b study aimed at establishing a dose-response relationship over a wide range of VAY736 doses, using change from baseline (BL) in the EULAR Sjogren’s Syndrome Disease Activity index (ESSDAI) over 24 Weeks (Wks) as the primary endpoint. Here we report Wk24 efficacy and safety. The study is ongoing with a second blinded treatment period up to Wk52.

Ianalumab Biosimilar - Research Grade, ichor.bio, ICH5587

Research Grade Ianalumab (HV599016), abinScience, HV599016